Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor, R.M., Burch, J.D., Magnuson, S., Ortwine, D.F., Chen, Y., De La Torre, K., Ding, X., Eigenbrot, C., Johnson, A., Liimatta, M., Liu, Y., Shia, S., Wang, X., Wu, L.C., Pei, Z.(2014) Bioorg Med Chem Lett 24: 2448-2452
- PubMed: 24767842 
- DOI: 10.1016/j.bmcl.2014.04.023
- Primary Citation of Related Structures:  
4PP9, 4PPA, 4PPB, 4PPC - PubMed Abstract: 
There is evidence that small molecule inhibitors of the non-receptor tyrosine kinase ITK, a component of the T-cell receptor signaling cascade, could represent a novel asthma therapeutic class. Moreover, given the expected chronic dosing regimen of any asthma treatment, highly selective as well as potent inhibitors would be strongly preferred in any potential therapeutic ...